The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
Abstract
Purpose: To assess the feasibility of administering XRP6258, a new taxane with a low affinity for the multidrug resistance 1 protein, as a 1-hour i.v. infusion every 3 weeks. The study also sought to determine the maximum tolerated dose and the recommended dose, to describe the pharmacokinetic (PK) behavior of the compound, and to seek preliminary evidence of anticancer activity. Experimental Design: Twenty-five patients with advanced solid malignancies were treated with 102 courses of XRP6258 at four dose levels ranging from 10 to 25 mg/m2. Dose escalation was based on the occurrence of dose-limiting toxicity (DLT) at each dose level, provided that PK variables were favorable. The maximum tolerated dose was defined as the dose at which at least two patients developed a DLT at the first course. Results: Neutropenia was the principal DLT, with one patient experiencing febrile neutropenia and two others showing prolonged grade 4 neutropenia at the 25 mg/m2 dose level. Nonhematologic toxicities, including nausea, vomiting, diarrhea, neurotoxicity, and fatigue, were generally mild to moderate in severity. XRP6258 exhibited dose-proportional PK, a triphasic elimination profile, a long terminal half-life (77.3 hours), a high clearance (mean CL, 53.5 L/h), and a large volume of distribution (mean Vss, 2,034 L/m2). Objective antitumor activity included partial responses in two patients with metastatic prostate carcinoma, one unconfirmed partial response, and two minor responses. Conclusion: The recommended phase II dose of XRP6258 on this schedule is 20 mg/m2. The general tolerability and encouraging antitumor activity in taxane-refractory patients warrant further evaluations of XRP6258.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,926
Kinetics of pharmacologic response
Holford, N. H. G., & Sheiner, L. B. (1982) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(82)90051-1 · Cited by 501
Taxol: Mechanisms of Action and Resistancea
HORWITZ, S. B., LOTHSTEIN, L., MANFREDI, J. J., MELLADO, W., PARNESS, J., ROY, S. N., SCHIFF, P. B., SORBARA, L., & ZEHEB, R. (1986) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1986.tb38455.x · Cited by 416
Hunter, J., Jepson, M. A., Tsuruo, T., Simmons, N. L., & Hirst, B. H. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82429-2 · Cited by 370
Wagner, J. G. (1968) · Journal of Theoretical Biology · doi:10.1016/0022-5193(68)90188-4 · Cited by 305
Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001
Baker, S. D., Verweij, J., Rowinsky, E. K., Donehower, R. C., Schellens, J. H. M., Grochow, L. B., & Sparreboom, A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.24.1883 · Cited by 286
Self-citationA population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation
Bruno, R., Vivier, N., Vergniol, J. C., De Phillips, S. L., Montay, G., & Sheiner, L. B. (1996) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353487 · Cited by 265
The taxoids: paclitaxel and docetaxel
Gelmon, K. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90754-4 · Cited by 243
Taxol: mechanisms of action and resistance.
Horwitz, S. B., Cohen, D., Rao, S., Ringel, I., Hj, S., & Yang, C.-P. (1993) · PubMed · Cited by 221
The blood-brain barrier and oncology: new insights into function and modulation
Bart, J., Groen, H. J. M., Hendrikse, N. H., van der Graaf, W. T. A., Vaalburg, W., & de Vries, E. G. E. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0194 · Cited by 179
Cited by
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Self-citationEvolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Falzone, L., Salomone, S., & Libra, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01300 · Cited by 908
Oncogenic protein interfaces: small molecules, big challenges
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3690 · Cited by 312
Eisenberger, M., Hardy-Bessard, A.-C., Kim, C. S., Géczi, L., Ford, D., Mourey, L., Carles, J., Parente, P., Font, A., Kacso, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1076 · Cited by 292
Self-citationImpact of taxanes on androgen receptor signaling
Dong, Y., Bai, S., & Zhang, B. (2019) · Asian Journal of Andrology · doi:10.4103/aja.aja_37_18 · Cited by 26
Metadata
- Authors
- Mita, A. C., Denis, L. J., Rowinsky, E. K., DeBono, J. S., Goetz, A. D., Ochoa, L., Forouzesh, B., Beeram, M., Patnaik, A., Molpus, K., Semiond, D., Besenval, M., & Tolcher, A. W.
- Venue
- Clinical Cancer Research
- Published
- 2009-01-15
- Volume
- 15
- Issue
- 2
- Pages
- 723-730
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2051905300
- Cited by
- 332
- References
- 15
- FWCI
- 16.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-0596
- The paper
- Mita, A. C., Denis, L. J., Rowinsky, E. K., DeBono, J. S., Goetz, A. D., Ochoa, L., Forouzesh, B., Beeram, M., Patnaik, A., Molpus, K., Semiond, D., Besenval, M., & Tolcher, A. W. (2009). Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-0596
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.